Cancer Science最新文献

筛选
英文 中文
SNRPC-DHX9-RelA Complex Drives Cell-Cycle Signaling and CDK4/6 Inhibitor Sensitivity in Hepatocellular Carcinoma. SNRPC-DHX9-RelA复合物驱动肝细胞癌细胞周期信号传导和CDK4/6抑制剂敏感性
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-11 DOI: 10.1111/cas.70589
Jiaojiao Xie, Yue Wu, Xiaohan Qian, Jingwen Huang, Tingting Jia, Saiyan Bian, Runzhou Ni, Xuying Zhao, Xiaoli Huang
{"title":"SNRPC-DHX9-RelA Complex Drives Cell-Cycle Signaling and CDK4/6 Inhibitor Sensitivity in Hepatocellular Carcinoma.","authors":"Jiaojiao Xie, Yue Wu, Xiaohan Qian, Jingwen Huang, Tingting Jia, Saiyan Bian, Runzhou Ni, Xuying Zhao, Xiaoli Huang","doi":"10.1111/cas.70589","DOIUrl":"10.1111/cas.70589","url":null,"abstract":"<p><p>SNRPC is a core spliceosomal protein, but its oncogenic function and therapeutic relevance in hepatocellular carcinoma (HCC) remain incompletely defined. Here, we found that SNRPC was upregulated in HCC tissues and was associated with adverse clinicopathological features and poor survival. In the TCGA-LIHC cohort, high SNRPC expression remained associated with poorer overall survival after multivariable adjustment. Gain- and loss-of-function studies showed that SNRPC promoted HCC cell proliferation and migration in vitro and tumor growth in vivo. Mechanistically, SNRPC interacted with DHX9 and RelA/p65 to form a functional complex that enhanced NF-κB signaling and downstream CDK4/6-E2F1 signaling. Mutational analysis showed that the ATP-binding residue K417 of DHX9 contributed to RelA/p65 Ser536 phosphorylation, supporting a functional role for DHX9 in this signaling complex. Consistently, SNRPC or DHX9 depletion altered cell-cycle distribution and reduced NF-κB-associated cell-cycle signaling. Finally, the CDK4/6 inhibitor palbociclib markedly suppressed the enhanced growth of SNRPC- or DHX9-overexpressing xenografts. These findings identify a non-canonical oncogenic function of SNRPC in HCC and provide a mechanistic rationale for further evaluating CDK4/6 inhibition in tumors characterized by activation of the SNRPC/DHX9 signaling network.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13754450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149395760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High AXL Expression and Stromal-Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers. 上消化道肿瘤中AXL高表达和基质血管生成免疫表型
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-11 DOI: 10.1111/cas.70594
Kyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, Akitaka Makiyama, Toshihiro Kudo, Kentaro Yamazaki, Koushiro Ohtsubo, Taroh Satoh, Chigusa Morizane, Shogen Boku, Eiji Oki, Naoki Takahashi, Fumio Nagashima, Shigenori Kadowaki, Takeshi Kato, Yoshito Komatsu, Yohei Kubota, Akihito Tsuji, Yukiko Fukuda, Naoko Iida, Taro Shibuki, Hideaki Bando, Karam Ashouri, Sandra Algaze, Heinz-Josef Lenz, Takayuki Yoshino
{"title":"High AXL Expression and Stromal-Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers.","authors":"Kyosuke Seguchi, Tadayoshi Hashimoto, Takao Fujisawa, Akitaka Makiyama, Toshihiro Kudo, Kentaro Yamazaki, Koushiro Ohtsubo, Taroh Satoh, Chigusa Morizane, Shogen Boku, Eiji Oki, Naoki Takahashi, Fumio Nagashima, Shigenori Kadowaki, Takeshi Kato, Yoshito Komatsu, Yohei Kubota, Akihito Tsuji, Yukiko Fukuda, Naoko Iida, Taro Shibuki, Hideaki Bando, Karam Ashouri, Sandra Algaze, Heinz-Josef Lenz, Takayuki Yoshino","doi":"10.1111/cas.70594","DOIUrl":"10.1111/cas.70594","url":null,"abstract":"<p><p>AXL, a receptor tyrosine kinase, has been implicated in epithelial-mesenchymal transition, angiogenesis, immune evasion, and therapeutic resistance, but its relevance in upper gastrointestinal cancers remains incompletely defined. We analyzed 337 patients with advanced gastric (n = 287) or esophageal (n = 50) cancer enrolled in SCRUM-Japan MONSTAR-SCREEN-2, whose tumors were profiled by whole-exome and whole-transcriptome sequencing. Patients were classified as AXL-high (n = 169) or AXL-low (n = 168) using cancer type-specific median transcripts-per-million cutoffs. Median follow-up was 14.1 months. AXL-high tumors were associated with shorter overall survival than AXL-low tumors (median, 12.9 versus 17.1 months; hazard ratio, 1.58; 95% confidence interval, 1.17-2.14; p = 0.003), consistently in gastric (hazard ratio, 1.47; p = 0.020) and esophageal (hazard ratio, 2.46; p = 0.027) cancer. This association persisted after adjustment for cancer type, age, sex, number of metastatic sites, microsatellite instability status, and tumor mutational burden (hazard ratio, 1.59; 95% confidence interval, 1.14-2.22; p = 0.007). Among microsatellite stable patients treated with immune checkpoint blockade, AXL expression was not associated with progression-free survival (hazard ratio, 0.83; 95% confidence interval, 0.61-1.14; p = 0.255). AXL-high tumors showed stromal and vascular expansion, regulatory T-cell enrichment, higher expression of fibroblast growth factor receptor 1, vascular endothelial growth factor receptors 1-3, and MET, and enrichment of epithelial-mesenchymal transition, angiogenesis, and transforming growth factor beta signaling. High AXL expression identifies a poor-prognosis stromal-angiogenic phenotype in upper gastrointestinal cancers and warrants prospective validation as a prognostic, rather than predictive, biomarker. Trial Registration: UMIN Clinical Trials Registry, UMIN000043899.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13752837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Descriptive Epidemiology in Cancer Research: A Coordinate System for Cancer Science. 癌症研究中的描述流行病学:癌症科学的坐标系统。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-10 DOI: 10.1111/cas.70591
Keitaro Matsuo, Hidemi Ito
{"title":"Descriptive Epidemiology in Cancer Research: A Coordinate System for Cancer Science.","authors":"Keitaro Matsuo, Hidemi Ito","doi":"10.1111/cas.70591","DOIUrl":"10.1111/cas.70591","url":null,"abstract":"<p><p>Descriptive epidemiology characterizes the distribution of cancer in populations. Its indicators are neither self-explanatory as facts nor sufficient grounds for causal narratives. Cancer registries, vital statistics, and follow-up systems make incidence, mortality, survival, and prevalence observable, but these measures depend on how cases, deaths, and populations are defined and recorded. We propose an interpretive coordinate system that locates cancer patterns by person, place, time, complementary indicators, and the processes generating these indicators. This framework characterizes burden, identifies unusual patterns and inequalities, and generates and constrains hypotheses. It examines whether population patterns are compatible with changes in diagnosis, screening, treatment, or policy. It does not by itself establish causation, reveal mechanisms, or estimate intervention effects. Here, we clarify what the principal indicators describe, how they are constructed, and how common overinterpretations can be avoided. We present principles and examples from gastric, thyroid, colorectal, and lung cancer to distinguish observed patterns from competing interpretations, identify additional information needed, and clarify which conclusions remain unjustified. Particular attention is given to denominators, age structure, age-period-cohort interpretation, bias, and the assumptions required for comparison and modeling. The aim is to enable cancer researchers to use descriptive epidemiology as a disciplined framework for interpreting population patterns rather than as background statistics or a substitute for causal inference.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13751226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal Integration Identifies C16orf74 as an EMT Regulator With Prognostic Relevance in HNSCC. 多模式整合确定C16orf74作为与HNSCC预后相关的EMT调节因子。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-10 DOI: 10.1111/cas.70548
Zhijun Huang, Tatsuhiko Anzai, Jin Lu, Yuki Fukawa, Aya Ushio, Naozumi Ishimaru, Katarzyna A Podyma-Inoue, Tetsuro Watabe
{"title":"Multimodal Integration Identifies C16orf74 as an EMT Regulator With Prognostic Relevance in HNSCC.","authors":"Zhijun Huang, Tatsuhiko Anzai, Jin Lu, Yuki Fukawa, Aya Ushio, Naozumi Ishimaru, Katarzyna A Podyma-Inoue, Tetsuro Watabe","doi":"10.1111/cas.70548","DOIUrl":"10.1111/cas.70548","url":null,"abstract":"<p><p>Head and neck squamous cell carcinoma (HNSCC) is an aggressive malignancy characterized by marked intratumoral heterogeneity and poor clinical outcomes. Epithelial-mesenchymal transition (EMT) promotes metastasis, immune evasion, and therapeutic resistance. However, the key molecular determinants underlying EMT-associated malignant states remain incompletely defined, and their translation into clinically accessible tools is challenging. In this study, we performed an integrative multiomics analysis to dissect malignant epithelial heterogeneity in HNSCC. Single-cell RNA sequencing (scRNA-seq) identified a highly malignant EMT epithelial subpopulation characterized by elevated genomic instability and terminal malignant states. Furthermore, an ensemble of machine learning algorithms prioritized C16orf74 as a key EMT-associated malignant regulator. Spatial transcriptomics localized C16orf74 spatially concentrated at invasive-front and transitory regions associated with distinct tumor microenvironmental niches. Gain- and loss-of-function assays confirmed that C16orf74 regulates EMT activation, migration, invasion, and tumor-sphere formation in HNSCC cells. Mechanistically, integrative regulon, transcriptomic, spatial, and functional analyses identified high-mobility group AT-hook 2 (HMGA2) as a candidate downstream mediator of C16orf74-associated EMT. To translate these biological insights into clinical practice, we developed an EMT-based pathomics prognostic model using hematoxylin and eosin-stained whole-slide images, which achieved robust prognostic stratification. Notably, high-risk group interpretably exhibited a positive correlation with C16orf74 expression, EMT enrichment, an immunosuppressive microenvironment, and resistance to standard chemotherapeutic agents. Collectively, our findings identify C16orf74 as a putative EMT regulator and develop a clinically accessible pathomics model for prognostic and therapeutic stratification in HNSCC.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13752527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149388334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sample-Related Factors Associated With FGFR Testing Validity in Urothelial Cancer: A Japanese THOR Post Hoc Analysis. 尿路上皮癌中与FGFR检测有效性相关的样本相关因素:日本THOR事后分析。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-09 DOI: 10.1111/cas.70588
Minoru Kato, Masaki Yoshida, Hiroshi Horio, Yohei Furukawa, Tatsuya Ote, Chisato Ohe
{"title":"Sample-Related Factors Associated With FGFR Testing Validity in Urothelial Cancer: A Japanese THOR Post Hoc Analysis.","authors":"Minoru Kato, Masaki Yoshida, Hiroshi Horio, Yohei Furukawa, Tatsuya Ote, Chisato Ohe","doi":"10.1111/cas.70588","DOIUrl":"10.1111/cas.70588","url":null,"abstract":"<p><p>Timely access to valid fibroblast growth factor receptor (FGFR) testing is essential for treatment selection in metastatic urothelial carcinoma; however, invalid results remain a barrier to timely treatment selection. We conducted a post hoc analysis of the Japanese subgroup of the Phase 3 THOR trial to describe FGFR testing validity across sample-related factors and explore its predictors. Among 612 patients with FGFR testing records, 563 (92.0%) had valid results, and FGFR alterations were detected in 82 of 563 (14.6%). The proportion of valid results tended to be lower in biopsy-derived samples than in surgical-resection samples (76.9%-83.3% vs. 92.3%-97.7%). Samples that provided invalid testing results had smaller median total tissue surface area (16.60 vs. 388.85 mm<sup>2</sup>) and target tumor surface area (2.00 vs. 85.10 mm<sup>2</sup>). In contrast, for upper tract urothelial carcinoma biopsies, even valid samples had small median total tissue and target tumor surface areas (22.60 and 7.55 mm<sup>2</sup>), underscoring that specimen source and collection method must be accounted for when interpreting surface area. In multivariable logistic regression, larger target tumor surface area was associated with higher test validity (adjusted odds ratio 1.10 per 10 mm<sup>2</sup> increase; 95% confidence interval 1.05-1.16), whereas neither archival sample age nor any of the defined fixation-duration categories was associated with validity. Most invalid results reflected insufficient tumor cells rather than RNA quality. Specimen source, collection method, and target tumor surface area should therefore be considered together when selecting samples to improve FGFR testing validity, leading to greater access to targeted therapy. Trial Registration: ClinicalTrials.gov identifier NCT03390504.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748882/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
3-Indoxyl Sulfate and O-Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer. 3-吲哚酚硫酸盐和o -乙酰肉碱是食管癌早期诊断的潜在新生物标志物。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-09 DOI: 10.1111/cas.70570
Kenji Hamada, Yohei Ozawa, Hiroshi Okamoto, Shinji Fukuda, Tomoyoshi Soga, Takaaki Abe, Hozumi Motohashi, Shohei Murakami, Takashi Kamei
{"title":"3-Indoxyl Sulfate and O-Acetylcarnitine Are Potential Novel Biomarkers for Early Diagnosis of Esophageal Cancer.","authors":"Kenji Hamada, Yohei Ozawa, Hiroshi Okamoto, Shinji Fukuda, Tomoyoshi Soga, Takaaki Abe, Hozumi Motohashi, Shohei Murakami, Takashi Kamei","doi":"10.1111/cas.70570","DOIUrl":"10.1111/cas.70570","url":null,"abstract":"<p><p>Esophageal cancer is the seventh most common cancer worldwide, and early detection is crucial for improving long-term survival. However, reliable noninvasive biomarkers for early-stage disease remain limited. In this study, we aimed to identify novel biomarkers for early-stage esophageal cancer through comprehensive metabolomic analyses of plasma and urine samples from patients and healthy individuals. Metabolomic profiling revealed that 3-indoxyl sulfate (3-IS) was consistently elevated in both plasma and urine of esophageal cancer patients. As esophageal cancer cells do not directly produce 3-IS, its elevation may reflect cancer-associated systemic metabolic alterations. O-acetylcarnitine (O-AC) was identified as the most significantly increased metabolite in plasma, and in vitro analyses suggested a possible association with tumor-related metabolic changes. Receiver operating characteristic analyses (ROC) demonstrated that the combined plasma and urinary 3-IS model achieved an area under the curve (AUC) of 0.863 in Stage I/II disease, whereas plasma O-AC achieved an AUC of 0.902. Bootstrap resampling provided internal validation; however, the discovery and evaluation were performed within the same single-center cohort. These results suggest that 3-IS and O-AC are promising candidate biomarkers that distinguish patients with esophageal cancer from healthy individuals, but further validation of their disease specificity and diagnostic performance is required in independent multicenter cohorts including clinically relevant disease-control groups.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
UHRF1 Supports PARP1 Protein Stability and Ovarian Cancer Progression by Limiting PARP1 Polyubiquitination. UHRF1通过限制PARP1多泛素化支持PARP1蛋白稳定性和卵巢癌进展。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-08 DOI: 10.1111/cas.70592
Yuying Chen, Linxiang Wu, Jihui Kang, Huishan Xu, Qin Ling, Siqi Yang, Tingting Sun, Huiling Lai, Hao Tan, Guofen Yang, Weipeng He
{"title":"UHRF1 Supports PARP1 Protein Stability and Ovarian Cancer Progression by Limiting PARP1 Polyubiquitination.","authors":"Yuying Chen, Linxiang Wu, Jihui Kang, Huishan Xu, Qin Ling, Siqi Yang, Tingting Sun, Huiling Lai, Hao Tan, Guofen Yang, Weipeng He","doi":"10.1111/cas.70592","DOIUrl":"10.1111/cas.70592","url":null,"abstract":"<p><p>Ubiquitin-like with PHD and RING finger domains 1 (UHRF1) is an epigenetic regulator with oncogenic activity, but its role in PARP1 protein homeostasis in ovarian cancer remains unclear. We assessed UHRF1 expression in public datasets and clinical specimens, tested UHRF1 depletion in ovarian cancer cells and mouse models, and examined UHRF1-PARP1 association, protein turnover, ubiquitination, and rescue. UHRF1 was elevated in ovarian tumor samples, and high expression was associated with adverse outcomes in the institutional tissue-microarray cohort. UHRF1 depletion reduced cell growth and migration, increased apoptosis, and reduced endpoint xenograft weight and volume. UHRF1 is associated with PARP1; its depletion reduced PARP1 protein without changing its mRNA, shortened its apparent half-life, and increased total PARP1-associated polyubiquitin. Re-expression of full-length UHRF1, but less effectively the TTD-deletion construct, restored PARP1 association and stability. In separate experiments, RNF4-targeting siRNA attenuated PARP1 loss and ubiquitination associated with UHRF1 depletion. Together, these findings identify UHRF1 as a regulator of PARP1 protein stability in ovarian cancer models and support contributions of the TTD-containing region and RNF4 to this regulation.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13745818/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149381409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study. 日本癌症患者综合基因组图谱应用的前景和时间进程:一项回顾性研究。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-03 DOI: 10.1111/cas.70561
Kuniko Sunami, Masashi Mikami, Masayuki Tanaka, Sona-Sanae Aoyagi, Kanae Togo
{"title":"Landscape and Time Course of Comprehensive Genomic Profiling Use in Japanese Patients With Cancer: A Retrospective Study.","authors":"Kuniko Sunami, Masashi Mikami, Masayuki Tanaka, Sona-Sanae Aoyagi, Kanae Togo","doi":"10.1111/cas.70561","DOIUrl":"10.1111/cas.70561","url":null,"abstract":"<p><p>Comprehensive genomic profiling (CGP) is standard for advanced solid tumors. Evidence reporting its real-world utilization pattern and time course for guided therapy is limited. This retrospective study in Japan assessed the real-world utility of CGP tests for advanced or metastatic solid tumors using data from the C-CAT registry from June 1, 2019, to August 23, 2025. We evaluated the proportion of patients who received genomically matched therapy with expert panel (EP) recommendation and their overall survival (OS) compared with patients who did not receive genomically matched therapy. The study population comprised 89,552 patients who underwent CGP: median age 64.0 (interquartile range: 54.0-72.0) years, with pancreatic cancer (13,827; 15.4%) and colorectal cancer (11,322; 12.6%) the most common tumor types. System-generated matched treatment options presented as reference information during EP review were identified in 80,185, of whom 77,337 (96.4%) received EP review, 37,245 (46.4%) were offered new therapeutic recommendations, and 7124 (8.9%) initiated EP-recommended therapies. Among 2049 patients who were newly identified with companion diagnostic (CDx)-related druggable alterations, 319 (15.6%) received matched therapies. Patients receiving matched therapies experienced longer OS compared with others in the overall cohort (median: 538 days vs. 356 days) and across cancer types. OS varied by the final treatment line before CGP testing, with earlier lines associated with longer survival in biliary tract, ovarian, pancreatic, and thyroid cancers. These findings highlight the need for timely CGP implementation to maximize the impact of precision oncology. Trial Registration: Japan Registry of Clinical Trials identifier: jRCT1030250365.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13732159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149326481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study. 基于人工智能的卵巢癌肿瘤浸润淋巴细胞及同源重组分析:JGOG3025-A1研究。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-01 Epub Date: 2026-07-10 DOI: 10.1111/cas.70474
Kohei Hamada, Junzo Hamanishi, Noriomi Matsumura, Akihiko Ueda, Shiro Takamatsu, Kosuke Yoshihara, Takayuki Nagasawa, Toshiyuki Seki, Akira Kikuchi, Etsuko Fujimoto, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Hisaaki Kudo, Katsutoshi Oda, Muneaki Shimada, Aikou Okamoto, Masaki Mandai
{"title":"AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.","authors":"Kohei Hamada, Junzo Hamanishi, Noriomi Matsumura, Akihiko Ueda, Shiro Takamatsu, Kosuke Yoshihara, Takayuki Nagasawa, Toshiyuki Seki, Akira Kikuchi, Etsuko Fujimoto, Mana Taki, Koji Yamanoi, Ryusuke Murakami, Hisaaki Kudo, Katsutoshi Oda, Muneaki Shimada, Aikou Okamoto, Masaki Mandai","doi":"10.1111/cas.70474","DOIUrl":"10.1111/cas.70474","url":null,"abstract":"<p><p>Understanding the tumor immune microenvironment, especially tumor-infiltrating lymphocytes (TILs), remains crucial in ovarian cancer. However, the distribution and prognostic significance of TILs across histological subtypes and genetic backgrounds remain unclear. As part of the JGOG3025-A1 study, diagnostic slides from 400 cases were collected. Two artificial intelligence-based cell classification models were used to evaluate the spatial distribution of TILs. The TIL score was calculated as the number of TILs divided by the analyzed area, and the immune-inflamed group was defined based on TIL scores. Among histological subtypes, high-grade serous carcinoma (HGSC) exhibited the highest TIL scores, clear cell carcinoma the lowest, and endometrioid carcinoma intermediate values. In HGSC, TIL scores did not significantly differ according to BRCA alteration or homologous recombination deficiency (HRD) status. The HRD/immune-inflamed group had the most favorable prognosis. In the homologous recombination-proficient population, the immune-inflamed group had better progression-free survival, whereas this trend did not appear for overall survival. In analyzes of the relationships between TIL levels and genomic structure, whole-genome doubling was associated with lower TIL infiltration in HRD tumors but showed no association in HRP tumors. In conclusion, HGSC showed the highest amount of TIL infiltration among subtypes, and prognostic stratification can be achieved by integrating pathology-based immunophenotypes and HRD status.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":"3160-3170"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13394630/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148425766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database. 中国东部地区与SEER数据库间恶性间皮瘤的流行病学及预后差异。
IF 4.3 2区 医学
Cancer Science Pub Date : 2026-11-01 Epub Date: 2026-07-21 DOI: 10.1111/cas.70481
Ningning Li, Ruting Wang, Wenya Zhang, Zulei Shao, Hongyu Lin, Guanai Bao, Weimin Mao, Zhongjian Chen
{"title":"Epidemiological and Prognostic Differences in Malignant Mesothelioma Between Eastern China and SEER Database.","authors":"Ningning Li, Ruting Wang, Wenya Zhang, Zulei Shao, Hongyu Lin, Guanai Bao, Weimin Mao, Zhongjian Chen","doi":"10.1111/cas.70481","DOIUrl":"10.1111/cas.70481","url":null,"abstract":"<p><p>Eastern China malignant mesothelioma (MM) presents distinct features-younger age, female predominance, and moremalignant peritoneal mesothelioma (MPeM)-contrasting with the Western profile of older males with malignant pleural mesothelioma (MPM). Robust survival data for this population are still unavailable. This retrospective study included 253 MM patients from Zhejiang Cancer Hospital (2010-2024; 222 from Zhejiang Province, ZJ cohort) to update regional epidemiology and compare survival with the Surveillance, Epidemiology, and End Results program (SEER). The ZJ cohort exhibited a younger median age at diagnosis (58 vs. 74 years), a higher proportion of females (62% vs. 24%), and a higher prevalence of MPeM (54% vs. 11%) relative to the SEER cohort. Overall survival (OS) was significantly prolonged in the ZJ cohort (median OS: 22 vs. 10 months), with survival benefits consistently observed across sex, age, and MPM subgroups. Multivariate Cox analysis revealed age as the only consistent independent prognostic factor in both ZJ and SEER cohorts. Following propensity score matching to minimize confounding, the ZJ cohort maintained a significantly longer survival in MPM but exhibited worse outcome in MPeM relative to SEER. Collectively, this study not only updated epidemiologic features for MM in Eastern China but also reported the unique survival patterns, uncovering inter-population heterogeneity. These findings emphasize the value of region-specific prognostic evidence and the limitations of directly applying Western data to Asian populations.</p>","PeriodicalId":48943,"journal":{"name":"Cancer Science","volume":" ","pages":"3146-3159"},"PeriodicalIF":4.3,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13394437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148537375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书